Search

Your search keyword '"Perrotta, Fabio"' showing total 32 results
Start Over Author "Perrotta, Fabio" Publisher mdpi ag
32 results on '"Perrotta, Fabio"'

3. Targeting Progression in Pulmonary Fibrosis: An Overview of Underlying Mechanisms, Molecular Biomarkers, and Therapeutic Intervention

Author

D’Agnano, Vito, primary, Mariniello, Domenica Francesca, additional, Ruotolo, Michela, additional, Quarcio, Gianluca, additional, Moriello, Alessandro, additional, Conte, Stefano, additional, Sorrentino, Antonio, additional, Sanduzzi Zamparelli, Stefano, additional, Bianco, Andrea, additional, and Perrotta, Fabio, additional

Published
2024
Full Text
View/download PDF

4. Comorbidities in COPD: Current and Future Treatment Challenges

Author

Mariniello, Domenica Francesca, primary, D’Agnano, Vito, additional, Cennamo, Donatella, additional, Conte, Stefano, additional, Quarcio, Gianluca, additional, Notizia, Luca, additional, Pagliaro, Raffaella, additional, Schiattarella, Angela, additional, Salvi, Rosario, additional, Bianco, Andrea, additional, and Perrotta, Fabio, additional

Published
2024
Full Text
View/download PDF

10. Strategies Tackling Viral Replication and Inflammatory Pathways as Early Pharmacological Treatment for SARS-CoV-2 Infection: Any Potential Role for Ketoprofen Lysine Salt?

Author

Mariniello, Domenica Francesca, primary, Allocca, Valentino, additional, D’Agnano, Vito, additional, Villaro, Riccardo, additional, Lanata, Luigi, additional, Bagnasco, Michela, additional, Aronne, Luigi, additional, Bianco, Andrea, additional, and Perrotta, Fabio, additional

Published
2022
Full Text
View/download PDF

15. Use of Ultrasonography to Discriminate Psoriatic Arthritis from Fibromyalgia: A Post-Hoc Analysis of the ULISSE Study

Author

Marchesoni, Antonio, primary, Macchioni, Pierluigi, additional, Gasparini, Stefania, additional, Perricone, Carlo, additional, Perrotta, Fabio Massimo, additional, Grembiale, Rosa Daniela, additional, Silvagni, Ettore, additional, Ramonda, Roberta, additional, Costa, Luisa, additional, Zabotti, Alen, additional, Curradi, Giacomo, additional, Gualberti, Giuliana, additional, Marando, Francesca, additional, and Salvarani, Carlo, additional

Published
2021
Full Text
View/download PDF

17. SARS-CoV-2: One Year in the Pandemic. What Have We Learned, the New Vaccine Era and the Threat of SARS-CoV-2 Variants

Author

Scialo, Filippo, primary, Vitale, Maria, additional, Daniele, Aurora, additional, Nigro, Ersilia, additional, Perrotta, Fabio, additional, Gelzo, Monica, additional, Iadevaia, Carlo, additional, Cerqua, Francesco Saverio, additional, Costigliola, Adriano, additional, Allocca, Valentino, additional, Amato, Felice, additional, Pastore, Lucio, additional, Castaldo, Giuseppe, additional, and Bianco, Andrea, additional

Published
2021
Full Text
View/download PDF

18. Impact of Physical Activity on Disability Risk in Elderly Patients Hospitalized for Mild Acute Diverticulitis and Diverticular Bleeding Undergone Conservative Management

Author

Rocca, Aldo, primary, Brunese, Maria Chiara, additional, Cappuccio, Micaela, additional, Scacchi, Andrea, additional, Martucci, Gennaro, additional, Buondonno, Antonio, additional, Perrotta, Fabio Massimo, additional, Quarto, Gennaro, additional, Avella, Pasquale, additional, and Amato, Bruno, additional

Published
2021
Full Text
View/download PDF

25. Adiponectin, Leptin, and Resistin Are Dysregulated in Patients Infected by SARS-CoV-2

Author

Fabio Perrotta, Filippo Scialò, Marta Mallardo, Giuseppe Signoriello, Vito D’Agnano, Andrea Bianco, Aurora Daniele, Ersilia Nigro, Perrotta, Fabio, Scialo, Filippo, Mallardo, Marta, Signoriello, Giuseppe, D’Agnano, Vito, Bianco, Andrea, Daniele, Aurora, and Nigro, Ersilia

Subjects
Inorganic Chemistry, Organic Chemistry, COVID-19, adipose tissue, HMW adiponectin, leptin, resistin, SARS-CoV-2, General Medicine, Physical and Theoretical Chemistry, Molecular Biology, Spectroscopy, Catalysis, Computer Science Applications
Abstract

Obesity, through adipose tissue (AT) inflammation and dysregulation, represents a critical factor for COVID-19; here, we investigated whether serum levels of adiponectin, HMW oligomers, leptin, and resistin are modulated and/or correlated with clinical and biochemical parameters of severe COVID-19 patients. This study included 62 severe COVID-19 patients; 62 age and sex-matched healthy subjects were recruited as a control group. Anthropometric and biochemical parameters were obtained and compared. Adiponectin, HMW oligomers, leptin, and resistin were analyzed by ELISA. The adiponectin oligomerization state was visualized by Western blotting. When compared to healthy subjects, total adiponectin levels were statistically lower in severe COVID-19 while, in contrast, the levels of leptin and resistin were statistically higher. Interestingly, HMW adiponectin oligomers negatively correlated with leptin and were positively associated with LUS scores. Resistin showed a positive association with IL-6, IL-2R, and KL-6. Our data strongly support that adipose tissue might play a functional role in COVID-19. Although it needs to be confirmed in larger cohorts, adiponectin HMW oligomers might represent a laboratory resource to predict patient seriousness. Whether adipokines can be integrated as a potential additional tool in the evolving landscape of biomarkers for the COVID-19 disease is still a matter of debate. Other studies are needed to understand the molecular mechanisms behind adipokine’s involvement in COVID-19. © 2023 by the authors.

Published
2023

26. SARS-CoV-2: One Year in the Pandemic. What Have We Learned, the New Vaccine Era and the Threat of SARS-CoV-2 Variants

Author

Maria Vitale, Aurora Daniele, Lucio Pastore, Felice Amato, Francesco Saverio Cerqua, Fabio Massimo Perrotta, Ersilia Nigro, Adriano Costigliola, Giuseppe Castaldo, Monica Gelzo, Valentino Allocca, Filippo Scialò, Andrea Bianco, Carlo Iadevaia, Scialo, F., Vitale, M., Daniele, A., Nigro, E., Perrotta, F., Gelzo, M., Iadevaia, C., Cerqua, F. S., Costigliola, A., Allocca, V., Amato, F., Pastore, L., Castaldo, G., Bianco, A., Scialo, Filippo, Vitale, Maria, Daniele, Aurora, Nigro, Ersilia, Perrotta, Fabio, Gelzo, Monica, Iadevaia, Carlo, Cerqua, Francesco Saverio, Costigliola, Adriano, Allocca, Valentino, Amato, Felice, Pastore, Lucio, Castaldo, Giuseppe, and Bianco, Andrea

Subjects
0301 basic medicine, medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), COVID19, QH301-705.5, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Coronaviru, Population, coronavirus, Medicine (miscellaneous), ACE2, Review, Disease, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, 0302 clinical medicine, renin angiotensin aldosterone system, Pandemic, medicine, 030212 general & internal medicine, Biology (General), Intensive care medicine, education, education.field_of_study, business.industry, SARS-CoV-2, kinin-kallikrein system, 030104 developmental biology, business
Abstract

Since the beginning of 2020, the new pandemic caused by SARS-CoV-2 and named coronavirus disease 19 (COVID 19) has changed our socio-economic life. In just a few months, SARS-CoV-2 was able to spread worldwide at an unprecedented speed, causing hundreds of thousands of deaths, especially among the weakest part of the population. Indeed, especially at the beginning of this pandemic, many reports highlighted how people, suffering from other pathologies, such as hypertension, cardiovascular diseases, and diabetes, are more at risk of severe outcomes if infected. Although this pandemic has put the entire academic world to the test, it has also been a year of intense research and many important contributions have advanced our understanding of SARS-CoV-2 origin, its molecular structure and its mechanism of infection. Unfortunately, despite this great effort, we are still a long way from fully understanding how SARS-CoV-2 dysregulates organismal physiology and whether the current vaccines will be able to protect us from possible future pandemics. Here, we discuss the knowledge we have gained during this year and which questions future research should address.

Published
2021

27. Mechanisms and Clinical Implications of Endothelial Dysfunction in Arterial Hypertension

Author

Pasquale Ambrosino, Tiziana Bachetti, Silvestro Ennio D’Anna, Brurya Galloway, Andrea Bianco, Vito D’Agnano, Antimo Papa, Andrea Motta, Fabio Perrotta, Mauro Maniscalco, Ambrosino, P., Bachetti, T., D'Anna, S. E., Galloway, B., Bianco, A., D'Agnano, V., Papa, A., Motta, A., Perrotta, F., Maniscalco, M., Ambrosino, Pasquale, Bachetti, Tiziana, D'Anna, Silvestro Ennio, Galloway, Brurya, Bianco, Andrea, D'Agnano, Vito, Papa, Antimo, Motta, Andrea, Perrotta, Fabio, and Maniscalco, Mauro

Subjects
arterial hypertension, exercise, cardiovascular disease, occupational medicine, outcome, heart failure, arginine, Pharmacology (medical), General Pharmacology, Toxicology and Pharmaceutics, chronic disease, endothelial dysfunction, rehabilitation
Abstract

The endothelium is composed of a monolayer of endothelial cells, lining the interior surface of blood and lymphatic vessels. Endothelial cells display important homeostatic functions, since they are able to respond to humoral and hemodynamic stimuli. Thus, endothelial dysfunction has been proposed as a key and early pathogenic mechanism in many clinical conditions. Given the relevant repercussions on cardiovascular risk, the complex interplay between endothelial dysfunction and systemic arterial hypertension has been a matter of study in recent years. Numerous articles have been published on this issue, all of which contribute to providing an interesting insight into the molecular mechanisms of endothelial dysfunction in arterial hypertension and its role as a biomarker of inflammation, oxidative stress, and vascular disease. The prognostic and therapeutic implications of endothelial dysfunction have also been analyzed in this clinical setting, with interesting new findings and potential applications in clinical practice and future research. The aim of this review is to summarize the pathophysiology of the relationship between endothelial dysfunction and systemic arterial hypertension, with a focus on the personalized pharmacological and rehabilitation strategies targeting endothelial dysfunction while treating hypertension and cardiovascular comorbidities.

Published
2022

28. Pulmonary Hypertension and Obesity: Focus on Adiponectin

Author

Fabio Perrotta, Ersilia Nigro, Germano Guerra, Adriano Costigliola, Andrea Bianco, Mariano Mollica, Aurora Daniele, Vito D'Agnano, Perrotta, Fabio, Nigro, Ersilia, Mollica, Mariano, Costigliola, Adriano, D'Agnano, Vito, Daniele, Aurora, Bianco, Andrea, and Guerra, Germano

Subjects
0301 basic medicine, obesity, Hypertension, Pulmonary, Myocytes, Smooth Muscle, Adipose tissue, adipocytokine, Inflammation, Review, 030204 cardiovascular system & hematology, Pharmacology, Catalysis, Inorganic Chemistry, lcsh:Chemistry, 03 medical and health sciences, 0302 clinical medicine, Insulin resistance, Mineralocorticoid receptor, pulmonary hypertension, medicine, Animals, Humans, Molecular Targeted Therapy, Physical and Theoretical Chemistry, Endothelial dysfunction, Molecular Biology, lcsh:QH301-705.5, Spectroscopy, PI3K/AKT/mTOR pathway, Adiponectin, adiponectin, business.industry, Organic Chemistry, Computer Science Applications1707 Computer Vision and Pattern Recognition, General Medicine, medicine.disease, Pulmonary hypertension, Computer Science Applications, Adipocytokine, Obesity, Vascular smooth muscle, 030104 developmental biology, lcsh:Biology (General), lcsh:QD1-999, vascular smooth muscle, Disease Susceptibility, medicine.symptom, business, Biomarkers, Signal Transduction
Abstract

Pulmonary hypertension is an umbrella term including many different disorders causing an increase of the mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg. Recent data revealed a strong association between obesity and pulmonary hypertension. Adiponectin is a protein synthetized by the adipose tissue with pleiotropic effects on inflammation and cell proliferation, with a potential protective role on the pulmonary vasculature. Both in vivo and in vitro studies documented that adiponectin is an endogenous modulator of NO production and interferes with AMP-activated protein kinase (AMPK) activation, mammalian target of rapamycin (mTOR), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κβ) signaling preventing endothelial dysfunction and proliferation. Furthermore, adiponectin ameliorates insulin resistance by mediating the biological effects of peroxisome proliferator-activated receptor-gamma (PPARγ). Therefore, adiponectin modulation emerged as a theoretical target for the treatment of pulmonary hypertension, currently under investigation. Recently, consistent data showed that hypoglycemic agents targeting PPARγ as well as renin⁻angiotensin system inhibitors and mineralocorticoid receptor blockers may influence pulmonary hemodynamics in different models of pulmonary hypertension.

Published
2019

29. Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease.

Author

Perrotta F, Sanduzzi Zamparelli S, D'Agnano V, Montella A, Fomez R, Pagliaro R, Schiattarella A, Cazzola M, Bianco A, and Mariniello DF

Abstract

Idiopathic pulmonary fibrosis (IPF) has traditionally been considered the archetype of progressive fibrotic interstitial lung diseases (f-ILDs), but several other f-ILDs can also manifest a progressive phenotype. Integrating genomic signatures into clinical practice for f-ILD patients may help to identify patients predisposed to a progressive phenotype. In addition to the risk of progressive pulmonary fibrosis, there is a growing body of literature examining how pharmacogenomics influences treatment response, particularly regarding the efficacy and safety profiles of antifibrotic and immunomodulatory agents. In this narrative review, we discuss current studies in IPF and other forms of pulmonary fibrosis, including systemic autoimmune disorders associated ILDs, sarcoidosis and hypersensitivity pneumonitis. We also provide insights into the future direction of research in this complex field.

Published
2024
Full Text
View/download PDF

30. High-Flow Nasal Cannula System in Respiratory Failure Associated with Interstitial Lung Diseases: A Systematic Review and Narrative Synthesis.

Author

Pagliaro R, Aronne L, Fomez R, Ferri V, Montella A, Sanduzzi Zamparelli S, Bianco A, and Perrotta F

Abstract

Background : High-flow nasal cannula (HFNC) therapy has emerged as a promising treatment modality for interstitial lung disease (ILD)-related respiratory failure. This systematic review aims to evaluate the efficacy and safety of HFNC therapy in patients with ILDs. Methods: A comprehensive literature search was conducted using major electronic databases to identify relevant studies investigating the use of HFNC therapy in ILD patients with respiratory failure. Outcome measures of interest included improvements in oxygenation, dyspnea relief, respiratory rate control, hospital length of stay, and mortality. Results: Twelve studies were analyzed with an overall population of 715 patients included. Idiopathic Pulmonary Fibrosis (IPF) was the most prevalent type of ILD. Evaluated clinical settings were acute (7 studies), chronic (2 studies), and end-stage (3 studies) ILDs. The HFNC as a support for acute respiratory failure seems not inferior to non-invasive ventilation while offering better comfort and patient's perception. Poor data are available about use in chronic/long-term or rehabilitative settings. In end of life/palliative care, an HFNC might improve quality of life. Despite the promising results, further research is warranted to establish optimal HFNC protocols, identify patient subgroups most likely to benefit, and explore long-term outcomes. Conclusions: Overall, the HFNC appears to be a valuable therapeutic option for managing respiratory failure in ILD patients, offering potential improvements in oxygenation and symptom relief.

Published
2024
Full Text
View/download PDF

31. Targeting Progression in Pulmonary Fibrosis: An Overview of Underlying Mechanisms, Molecular Biomarkers, and Therapeutic Intervention.

Author

D'Agnano V, Mariniello DF, Ruotolo M, Quarcio G, Moriello A, Conte S, Sorrentino A, Sanduzzi Zamparelli S, Bianco A, and Perrotta F

Abstract

Interstitial lung diseases comprise a heterogenous range of diffuse lung disorders, potentially resulting in pulmonary fibrosis. While idiopathic pulmonary fibrosis has been recognized as the paradigm of a progressive fibrosing interstitial lung disease, other conditions with a progressive fibrosing phenotype characterized by a significant deterioration of the lung function may lead to a burden of significant symptoms, a reduced quality of life, and increased mortality, despite treatment. There is now evidence indicating that some common underlying biological mechanisms can be shared among different chronic fibrosing disorders; therefore, different biomarkers for disease-activity monitoring and prognostic assessment are under evaluation. Thus, understanding the common pathways that induce the progression of pulmonary fibrosis, comprehending the diversity of these diseases, and identifying new molecular markers and potential therapeutic targets remain highly crucial assignments. The purpose of this review is to examine the main pathological mechanisms regulating the progression of fibrosis in interstitial lung diseases and to provide an overview of potential biomarker and therapeutic options for patients with progressive pulmonary fibrosis.

Published
2024
Full Text
View/download PDF

32. Exploring the Role of Krebs von den Lungen-6 in Severe to Critical COVID-19 Patients.

Author

D'Agnano V, Scialò F, Perna F, Atripaldi L, Sanduzzi S, Allocca V, Vitale M, Pastore L, Bianco A, and Perrotta F

Abstract

COVID-19 encompasses a broad spectrum of clinical conditions caused by SARS-CoV-2 infection. More severe cases experience acute respiratory and/or multiorgan failure. KL-6 is a glycoprotein expressed mainly from type II alveolar cells with pro-fibrotic properties. Serum KL-6 concentrations have been found in patients with COVID-19. However, the relevance of KL-6 in patients with severe and critical COVID-19 has not been fully elucidated. Methods: Retrospective data from consecutive severe to critical COVID-19 patients were collected at UOC Clinica Pnuemologica “Vanvitelli”, A.O. dei Colli, Naples, Italy. The study included patients with a positive rhinopharyngeal swab for SARS-CoV-2 RNA with severe or critical COVID-19. Results: Among 87 patients, 24 had poor outcomes. The median KL-6 value in survivors was significantly lower when compared with dead or intubated patients (530 U/mL versus 1069 U/mL p < 0.001). KL-6 was correlated with body mass index (BMI) (r: 0.279, p: 0.009), lung ultrasound score (LUS) (r: 0.429, p < 0.001), Chung Score (r: 0.390, p < 0.001). KL-6 was associated with the risk of death or oro-tracheal intubation (IOT) after adjusting for gender, BMI, Charlson Index, Chung Score, and PaO2/FIO2 (OR 1.003 95% CI 1.001−1.004, p < 0.001). Serum KL-6 value of 968 has a sensitivity of 79.2%, specificity of 87.1%, PPV 70.4%, NPV 91.5%, AUC: O.85 for risk of death or IOT. Conclusions: The presented research highlights the relevance of serum KL-6 in severe to critical COVID-19 patients in predicting the risk of death or IOT., Competing Interests: The authors declare no conflict of interest.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results